

Supplementary Figure 17. Activation of TLR5 via paracrine signaling. (a) Model underlying the hypothetical activation of TLR5 in ERα-positive cancer cells with heterogenous response to endocrine therapy (apoptotic-persister). (b) Immunofluorescence analysis of histone H2B (nuclear marker) and HMGB1 in pre-treatment MCF7 vs. oestrogen deprived MCF7. (c) Enzyme-linked immunosorbent assay (ELISA) assay of cell-cultured conditioned media from MCF7 cells adapting to oestrogen deprivation (entering dormancy). Data include three independent seeding density. Each experiment was carried out in triplicates. Average and standard deviations are plotted for each timepoint. (d) Cell growth dynamics of MCF7 cells under oestrogen deprivation (-E2) and HMGB1 supplementation were monitored by tracking the total number of H2B-positive nuclei with continuous live imaging over the course of 21 days. Each datapoint represents the average and 95% CI of 16 replicates.